{"DataElement":{"publicId":"6488241","version":"1","preferredName":"Tyrosine Kinase Inhibitor Administer Type","preferredDefinition":"Information for Tyrosine Kinase Inhibitor (TKI) drug try being administered.","longName":"TKI_AGNT_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6488237","version":"1","preferredName":"Tyrosine Kinase Inhibitor Administer","preferredDefinition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation._To dispense, apply, or tender something to another, such as administering a medicine.","longName":"2934694v1.0:6488235v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2934694","version":"1","preferredName":"Tyrosine Kinase Inhibitor","preferredDefinition":"Substances that inhibit tyrosine kinase enzymes, involved with the transduction and processing of many extracellular and intracellular signals including cell proliferation. They have numerous applications in the prevention and treatment of cancer. (NCI)","longName":"C1967","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"71935A3C-4B29-863D-E040-BB89AD434A00","latestVersionIndicator":"Yes","beginDate":"2009-08-20","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-08-20","modifiedBy":"ONEDATA","dateModified":"2009-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6488235","version":"1","preferredName":"Administer","preferredDefinition":"To dispense, apply, or tender something to another, such as administering a medicine.","longName":"C64912","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administer","conceptCode":"C64912","definition":"To dispense, apply, or tender something to another, such as administering a medicine.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"78717601-431B-5EB5-E053-F662850A4868","latestVersionIndicator":"Yes","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ONEDATA","dateModified":"2018-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78717601-432C-5EB5-E053-F662850A4868","latestVersionIndicator":"Yes","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"LEEW","dateModified":"2018-11-28","changeDescription":"AAML18P1","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6488239","version":"1","preferredName":"Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6488239v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"787235A7-BD0D-13FD-E053-F662850A0072","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ONEDATA","dateModified":"2018-10-17","deletedIndicator":"No"},{"value":"Bosutinib","valueDescription":"Bosutinib","ValueMeaning":{"publicId":"3379565","version":"1","preferredName":"Bosutinib","longName":"3379565","preferredDefinition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bosutinib","conceptCode":"C60809","definition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-371C-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"787235A7-BD17-13FD-E053-F662850A0072","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ONEDATA","dateModified":"2018-10-17","deletedIndicator":"No"},{"value":"Ponatonib","valueDescription":"Ponatonib","ValueMeaning":{"publicId":"6488240","version":"1","preferredName":"Ponatonib","longName":"6488240","preferredDefinition":"Ponatonib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"787235A7-BD21-13FD-E053-F662850A0072","latestVersionIndicator":"Yes","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ONEDATA","dateModified":"2018-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"787235A7-BD3A-13FD-E053-F662850A0072","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ONEDATA","dateModified":"2018-10-17","deletedIndicator":"No"},{"value":"Nilotinib","valueDescription":"Nilotinib","ValueMeaning":{"publicId":"5805905","version":"1","preferredName":"Nilotinib","longName":"5805905","preferredDefinition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib","conceptCode":"C48375","definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA044AC-B549-3351-E053-F662850A8B45","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"787235A7-BD44-13FD-E053-F662850A0072","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ONEDATA","dateModified":"2018-10-17","deletedIndicator":"No"},{"value":"Dasatinib","valueDescription":"Dasatinib","ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"787235A7-BD4E-13FD-E053-F662850A0072","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ONEDATA","dateModified":"2018-10-17","deletedIndicator":"No"},{"value":"Imatinib","valueDescription":"Imatinib","ValueMeaning":{"publicId":"3228378","version":"1","preferredName":"Imatinib","longName":"3228378","preferredDefinition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib","conceptCode":"C62035","definition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A160434C-66D5-A92B-E040-BB89AD43423D","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"787235A7-BD58-13FD-E053-F662850A0072","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ONEDATA","dateModified":"2018-10-17","deletedIndicator":"No"},{"value":"Not documented","valueDescription":"Not documented","ValueMeaning":{"publicId":"5978255","version":"1","preferredName":"Not documented","longName":"5978255","preferredDefinition":"Not documented","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"591206A2-5D89-061B-E053-F662850A94A3","latestVersionIndicator":"Yes","beginDate":"2017-09-13","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-09-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"888E3384-35C0-7D29-E053-F662850AE7D7","beginDate":"2019-05-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2019-05-10","modifiedBy":"ONEDATA","dateModified":"2019-05-10","deletedIndicator":"No"},{"value":"Bafetinib","valueDescription":"Bafetinib","ValueMeaning":{"publicId":"6755472","version":"1","preferredName":"Bafetinib","longName":"6755472","preferredDefinition":"Bafetinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"888E3384-35CA-7D29-E053-F662850AE7D7","latestVersionIndicator":"Yes","beginDate":"2019-05-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2019-05-10","modifiedBy":"ONEDATA","dateModified":"2019-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"888E3384-35E3-7D29-E053-F662850AE7D7","beginDate":"2019-05-10","endDate":null,"createdBy":"ROSSD","dateCreated":"2019-05-10","modifiedBy":"ONEDATA","dateModified":"2019-05-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"787235A7-BCF7-13FD-E053-F662850A0072","latestVersionIndicator":"Yes","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ROSSD","dateModified":"2019-05-10","changeDescription":"AAML18P1","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"TKI agent:","type":"Preferred Question Text","description":"TKI agent:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"TKI administered","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7872434D-11F2-13CF-E053-F662850A6D83","latestVersionIndicator":"Yes","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ROSSD","dateModified":"2019-05-10","changeDescription":"AAML18P1","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}